Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT03770533 Completed - Clinical trials for Patients Presenting With Suspicion of Infection to the ED

Identifying Patients With Suspicion of Infection in the ED Who Have Low Disease Severity Using MR-proADM - Pilot Study

IDEAL
Start date: December 14, 2018
Phase: N/A
Study type: Interventional

Emergency departments (ED) are becoming increasingly over-crowded, with patients facing prolonged waiting times. Therefore, a safe and rapid assessment that identifies patients with low severity that could be treated as outpatients is essential for improving the workflow within the ED. The rationale of this IDEAL study is to provide guidance to safely decrease the number of hospital admissions through identification of low risk patients with the biomarker MR-proADM. This will be tested in a pilot study first.

NCT ID: NCT03768635 Completed - Clinical trials for Bone and Joint Infection

Necrotizing External Otitis : Study in a Regional Bone and Joint Infection Reference Center

Start date: January 1, 2006
Phase:
Study type: Observational

The malignant external otitis is a rare disease which arises more frequently at the elderly and the diabetics patients. To our knowledge, there are few data and it is not wellc known byclinicians. Nevertheless it exposes to neurological complications potentially serious and crippling.

NCT ID: NCT03764943 Completed - Breast Cancer Clinical Trials

Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction

Start date: February 1, 2019
Phase: Phase 3
Study type: Interventional

This study is designed to test the following hypothesis: patients undergoing immediate alloplastic and autologous breast reconstruction following mastectomy that receive preoperative immunonutrition will experience a reduction in wound complications in the 30-day postoperative period compared to a standard of care control group (retrospective chart review) of 264 (132 alloplastic + 132 autologous) consecutive breast reconstruction patients prior to 5/25/2018.

NCT ID: NCT03762473 Completed - Clinical trials for Renal Transplant Infection

Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection

Start date: May 9, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess if the use of Envarsus in place of Tacrolimus-immediate release (IR) in rapid metabolizers post kidney transplant will reduce incidence of BK infection. Efficacy evaluations will include measurement of urine and serum BK values at specified time points and review of any biopsy for BK virus nephropathy. Incidence of rejection, graft failure, and graft dysfunction will also be measured at specified time points.

NCT ID: NCT03757429 Completed - Clinical trials for Respiratory Tract Infections

Inflammatory Mediators Associated With Infection by Respiratory Syncytial Virus

IMAR
Start date: April 1, 2018
Phase:
Study type: Observational

Infection with human respiratory syncytial (RS) virus is the most common cause of hospital stay due to pediatric lower respiratory tract infection. An exaggerated immune response contributes to the pathogenesis and small children may have over reactive airways for a long time after an infection. New research has shown that polymorphonuclear leukocytes (PMNs) are stimulated by the virus. Besides fighting the infection they also cause collateral damage to the host. Among other mechanisms PMNs stimulates mucus formation that affects breathing. They also secrete enzymes, toxic proteins and free radicals that may cause harm to lung tissue and airways. The current project strives towards identifying and quantifying inflammatory mediators in sputum, urine and blood of children with severe RS-virus infection. The ultimate aim of the project is to, in detail, describe proteins contributing to the pathogenesis of the disease.

NCT ID: NCT03756506 Completed - Infection Clinical Trials

The Use of a Novel Microbicidal Liquid Polymer for the Reduction of Pin Track Infection

Start date: November 7, 2018
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate additional clinical uses for the polymer, which is a FDA approved, 510k, medical device, but has not been approved for use on patients with pin track sites as a way to lower the infection rate and is investigational for this purpose. The approved uses include wound care and post-operative care. About 13 subjects will take part in this study.

NCT ID: NCT03750721 Completed - Clinical trials for Bone and Joint Infection

Staphylococcal Acute Post-Operative PJI Treated With 'DAIR' And Impact Of Rifampin

IPASTAPH
Start date: April 1, 2018
Phase:
Study type: Observational

S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.

NCT ID: NCT03750162 Completed - Clinical trials for Root Canal Infection

Bacteria Elimination in Retreatment Cases Using Different Disinfection Techniques

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Nonsurgical root canal retreatment may become essential when the initial endodontic treatment fails because of the persistent intracanal or extracanal infections.It has been stated that the one of the main cause of posttreatment disease is the persistent or reintroduced microorganism such as enterococcus faecalis. Supplementary disinfection techniques such as irrigation agitation methods can help elimination of bacteria from root canal systems. The aim of this in vivo study was to compare the effect of passive ultrasonic irrigation, manual dynamic activation and photodynamic therapy in reducing bacterial load in endodontic retreatment cases with periradicular lesion by using polymerase chain reaction (PCR)in a single visit root canal treatment.

NCT ID: NCT03749291 Completed - Clinical trials for Microbial Colonization

Motivational Intervention on the Gut Microbiota of Obese Children

MICROBEkids
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Animal models and studies on small samples of obese adults have shown that gut microbial diversity and certain types of bacteria could predict the efficacy of the dietetic treatment to improve body mass index (BMI) and the components of metabolic syndrome (MetS). Gut microbiota could distinguish the obese with metabolic syndrome patient than that metabolically healthy. Dietetic therapy could induce changes in the microbiota that could lead to improvement of BMI and the components of the MetS. The aim of MICROBEkids is to test whether the motivational intervention a motivational intervention (OBEMAT2.0) (PI15/00970) is more effective than the conventional intervention to increase the gut microbial diversity and, as a consequence, to improve BMI and MetS components. The role of gut microbiota (through modulation of the short chain fatty acids) will be analyzed as cardiovascular risk factor and as predictor of treatment success. These objectives will be achieved through a clustered clinical trial design with an intervention group that will receive a motivational therapy compared to a control group that will receive a conventional intervention, both during 12 months. The study sample are 319 children (n= 167 in the intervention group) that were enrolled in the clinical trial OBEMAT2.0 (PI15/00970), have had a comprehensive clinical assessment before the intervention (ages 8 to 14) and after 12 months (+3) of therapy (ages 9 to 15) and furthermore have participated in a biological samples collection for the investigation on childhood obesity (COLOBEPED, reference C.0004585).

NCT ID: NCT03748992 Completed - Clinical trials for Nontuberculous Mycobacterium Infection

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

Start date: January 28, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of open-label exposure of gNO in patients with NTM lung disease. Subjects will receive the study drug by inhaling through a nasal mask. Subjects will be treated for 3 weeks (5 days per week) and followed monthly for 3 months.